CoChat

Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL

The DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index.

Abstract

Background Cholinergic deficits might contribute to vascular cognitive impairment. Trials of cholinesterase inhibitors in patients with vascular dementia are difficult because of heterogeneous disease mechanisms and overlap between vascular and Alzheimer's disease (AD) pathology in the age-group recruited. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) is a genetic form of subcortical ischaemic vascular dementia. It represents a homogeneous disease process, and because of CADASIL's early onset, comorbid AD pathology is rare. We did a multicentre, 18-week, placebo-controlled, double-blind, randomised parallel-group trial to determine whether the cholinesterase inhibitor donepezil improves cognition in patients with CADASIL.Methods 168 patients with CADASIL (mean age 54.8 years) were assigned to 10 mg donepezil per day (n=86) or placebo (n=82) by a computer-generated randomisation protocol. Inclusion criteria included a mini-mental state examination (MMSE) score of 10-27 or a trail making test (TMT) B time score at least 1.5 SD below the mean, after adjustment for age and education. The primary endpoint was change from baseline in the score on the vascular AD assessment scale cognitive subscale (V-ADAS-cog) at 18 weeks. Secondary endpoints included scores on the ADAS-cog, MMSE, TMT A time and B time, Stroop, executive interview-25 (EXIT25), CLOX, disability assessment for dementia, and sum of boxes of the clinical dementia rating scale. Analysis was done by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00103948.Findings 161 patients were analysed. There was no significant difference between donepezil (n=84) and placebo (n=77) in the primary endpoint. The least-squares mean change from baseline score was -0.81 (SE 0.59) in the placebo group and -0.85 (SE 0.57) in the donepezil group (p=0.956). There was a significant treatment effect favouring donepezil on the following secondary outcomes: TMT B time (p=0.023), TMT A time (p=0.015), and EXIT25 (p=0.022). Ten donepezil-treated patients discontinued treatment due to adverse events compared to seven placebo-treated patients.Interpretation Donepezil had no effect on the primary endpoint, the V-ADAS-cog score in CADASIL patients with cognitive impairment. Improvements were noted on several measures of executive function, but the clinical relevance of these findings is not clear. Our findings may have implications for future trial design in subcortical vascular cognitive impairment.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(08)70046-2

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 41 references

Cited by

See all 284

Metadata

Authors
Dichgans, M., Markus, H. S., Salloway, S., Verkkoniemi, A., Moline, M., Wang, Q., Posner, H., & Chabriat, H. S.
Affiliations
  • Ludwig-Maximilians-Universität München (DE)
  • St George's, University of London (GB)
  • Butler Hospital (US)
  • Helsinki University Hospital (FI)
  • Eisai (United States) (US)
  • Pfizer (United States) (US)
  • Inserm (FR)
Corresponding author
Dichgans, Martin
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2008-04
Volume
7
Issue
4
Pages
310-318
ISSN
1474-4422 (ISSN-L)
OpenAlex
W2127553032
Cited by
264
References
43
Citations by year
2026: 11 · 2025: 6 · 2024: 16 · 2023: 7 · 2022: 12 · 2021: 19 · 2020: 10 · 2019: 10 · 2018: 10 · 2017: 19 · 2016: 11 · 2015: 15 · 2014: 21 · 2013: 14 · 2012: 18
FWCI
15.18
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet Neurology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Eisai
  • National Institutes of Health
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Clinical Neurology › Cerebrovascular and genetic disorders
Keywords
donepezil, cholinesterase inhibitors, CADASIL, subcortical vascular cognitive impairment, vascular dementia, cholinergic deficit, cognitive function, executive function, Trail Making Test, early-onset dementia, Alzheimer's disease comorbidity, Disability Assessment for Dementia, Clinical Dementia Rating
MeSH terms
Donepezil, Adult, Aged, Cognition Disorders, Double-Blind Method, Female, Humans, Indans, International Cooperation, Male, Mental Status Schedule, Middle Aged, Neuropsychological Tests, Piperidines, Problem Solving, Confidence Intervals, Nootropic Agents, CADASIL

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. https://app.cochat.ai/papers/10.1016/s1474-4422(08)70046-2
The paper
Dichgans, M., Markus, H. S., Salloway, S., Verkkoniemi, A., Moline, M., Wang, Q., Posner, H., & Chabriat, H. S. (2008). Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(08)70046-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.